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Abstract
Background:  The incidence of oral and pharyngeal (including oral cavity, oropharynx and
hypopharynx) carcinoma increases rapidly in Asia and South Pacific because of betel quid chewing.
Thus far, large-scale epidemiological studies are not available yet to stratify these patients by their
risks of developing a second primary cancer in the digestive tract including esophagus, stomach,
colon, and rectum.
Methods: A population-based study was conducted using the database from the Taiwan National
Cancer Registry for the period 1979-2003. We quantified standardized incidence ratios (SIRs) and
cumulative incidence of second primary cancers among 33,787 patients with initial diagnoses of oral
and pharyngeal carcinoma.
Results: Among these four digestive tract organs, the esophagus was the only site of second
cancer with excess risk in patients with oral and pharyngeal carcinoma. The incidence and risk of
developing a second primary esophageal cancer differed by the site of the primary index tumor,
most frequently seen in hypopharyngeal cancer (71/4,218 = 1.68%, SIR = 22.76, 95% CI 17.77-
28.70), followed by oropharyngeal cancer (30/3,403 = 0.88%, SIR = 14.29, 95% CI 9.64-20.39) and
the least in oral cavity cancer (99/26,166 = 0.38%, SIR = 5.57, 95% CI 4.53-6.78). In addition, the
risk was extraordinarily high for patients with a follow-up interval  1 year and those with first
primary cancer diagnosed at age 50. These patients may justify more close surveillance.
Conclusion: The present study represents the first population-based study in Asia attempting to
stratify the patients of oral and pharyngeal carcinoma by their risk of developing a second
esophageal cancer. It helps identify patients at high risk and tailor the application of intense follow-
up surveillance to the estimated risk in each individual case.
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Background
The incidence of oral and pharyngeal (including oral cav-
ity, oropharynx and hypopharynx) carcinoma is increas-
ing rapidly in Asia and South Pacific, which includes
Taiwan [1,2]. It affected more men than women. In addi-
tion to tobacco smoking and alcohol drinking, betel quid
chewing has been identified as a significant etiological
factor in this area [3]. Oral premalignancies are common
in betel quid chewers and about 10% of these undergo
malignant transformation. In Taiwan, 17% adult males
chewing betel quid, oral and pharyngeal carcinoma has
become the malignancy with the fastest increasing inci-
dence [4]. In the past 20 years, its age-standardized inci-
dence rate has increased from 6.04 per 100,000 men in
1986 to 26.36 in 2000, and 32.4 in 2005 [5], strikingly
higher than the incidences of the United States and Can-
ada (16 and 13 per 100,000 men in 2004, respectively)
[6,7]. Despite modern treatment modalities, the 5-year
survival rate of oral and pharyngeal carcinoma has
remained essentially unchanged over the past decades,
ranging from 40 to 50% [8,9]. This is partly because most
patients are often not diagnosed until a late stage and
therefore, an oral screening program can not be overem-
phasized in the high-risk population. The other major
cause of death is the high incidence rate of second primary
malignancies which impact survival rates the greatest in
patients with early-stage disease. The survival after second
cancers varies by the site of the second cancer, with
esophagus or lung being the worst [10].
The increased risk of second primary esophageal cancer
among patients with a first primary oral and pharyngeal
carcinoma was reported [11-13], yet there has been lim-
ited to single-institutional data, prejudiced by selection
bias or small sample size. In 2008, a large-scale study
assessed the risk of second primary cancers following a
first primary esophageal cancer as well as the risk of
esophageal cancer as a second primary [14]. The dataset
for analysis was pooled from 13 cancer registries located
in Europe, Australia, Canada, and Singapore; of these,
only 4.9% cases were in Asia. An excess of second primary
esophageal cancer following first primary cancers of the
oral and pharyngeal carcinoma was confirmed. To date,
there have been controversial opinions regarding routine
panendoscopy performed for every patient at the time of
initial work-up or in the follow-up [15-19]. Cost-effective-
ness is the greatest concern. For cost-saving, the optimal
strategy is to identify the subgroup of patients at the high-
est risk for second primary esophageal cancer. Thus far,
large-scale epidemiological studies are not available yet,
particularly in the high incidence found of South-East
Asia, to stratify oral and pharyngeal carcinoma patients by
their risks of developing a second primary cancer in the
digestive tract including esophagus, stomach, colon, and
rectum. To achieve this goal, we conducted a population-
based study using a database from the Taiwan Cancer Reg-
istry that included a total of 33,787 subjects with initial
diagnoses of oral and pharyngeal carcinoma between
1979 and 2003. This study is, to our knowledge, the larg-
est population-based study from a high-incidence area.
Methods
Data sources
We quantified second cancer incidences among 39,118
patients with initial diagnoses of oral and pharyngeal car-
cinoma, which included the primary cancer originating in
the oral cavity (ICD-9:140-145 except 142), oropharynx
(including the soft palate, tongue base and tonsil; ICD-9:
146, 149) and hypopharynx (including pypopharynx and
pyriform sinus; ICD-9: 148), who were reported to the
Taiwan Cancer Registry (TCR) http://crs.cph.ntu.edu.tw
between 1 January, 1979 and 31 December, 2003. TCR
was founded in 1979 and financially supported by the
National Department of Health with the aim of estimat-
ing the cancer incidence in Taiwan. It is a population-
based cancer registry that covered 22 million people in
2003. Hospitals with > 50 beds were obliged to submit
information on newly-diagnosed cancer patients to the
TCR, which reimburses the hospitals on the basis of num-
bers of cases reported in order to reduce the likelihood of
under-reporting. All cancer registry databases in the TCR
have been systemically converted to International Classi-
fication of Diseases, 9th Revision codes [20], and linked
with death certificates from the National Death Database.
Persons not identified by this process were therefore con-
sidered to be alive for the purpose of the current study
(passive follow-up). Coding of multiple primaries fol-
lowed a common set of rules proposed by the Interna-
tional Agency of Cancer Registries (IACR) and the
International Agency for Research on Cancer (IARC) [21].
Informed consent was not required because all registry
records are anonymous and open to the public.
To assess the age of onset accurately, estimate person-year
follow-up and minimize potentially unconfirmed cancer
diagnosis in this study cohort, 5,331 patients were
excluded from analysis because they met one or more of
the following criteria: (1) missing birth dates or unknown
gender (522 cases), (2) missing last follow-up date or
death status (2,570 cases), (3) second cancer diagnosis or
death occurring less than 1 month after the primary oral
and pharyngeal cancer (2,195 cases), or (4) age under 20
years old (165 cases). As a result, a total of 33,787 cases
(30,176 males and 3,611 females) were included in the
analysis. For subsequent risk analyses, the primary cancers
were further stratified by anatomic site of origin into oral
cavity (ICD-9: 140, 141, 143, 144, 145), oropharynx
(ICD-9: 146, 149) and hypopharynx (ICD-9: 148).BMC Cancer 2009, 9:373 http://www.biomedcentral.com/1471-2407/9/373
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Statistical analysis
To quantify the excess of second malignancies after diag-
nosis of primary oral and pharyngeal carcinoma, we cal-
culated the standardized incidence ratios (SIRs) [22] and
the corresponding 95% confidence intervals (CIs) for all
types of second primary cancers. SIRs were taken as the
ratio of the observed number (O) of second cancers to the
expected number (E), which was obtained by assuming
that these persons experienced the same cancer incidence
as the corresponding general population. The number of
person-years at risk was defined as the number of years
from the date of initial primary cancer diagnosis to the
date of death, date of last follow-up, date of diagnosis of
second primary cancer, or the end of the study period (31
December, 2003), whichever came first. The person-years
of observation for each gender, 5-year age group, 5-year
period (1979-1983, 1984-1988, 1989-1993, 1994-1998,
1999-2003) and time since entry to the cohort (1, 2-5
and >5 years) were multiplied by the incidence rates of
cancers for the Taiwanese population. The corresponding
products were summed over all ages and calendar years to
yield the expected number of second cancer at each site.
Confidence intervals of SIRs were based on the assump-
tion of a Poisson distribution of second cancer cases.
Cumulative incidence rates for occurrence of second can-
cers were calculated in the survivors' cohort, with death
treated as a competing risk according to the method of
Kalbfleisch and Prentice [23]. Briefly, this method allows
for the fact that patients who die are no longer at risk for
second cancers, so it differs from the cumulative incidence
estimated by the Kaplan-Meier method, which treats com-
peting events as censored at the time they occurred. Gray's
test [24] was used to assess the statistical differences of
cumulative incidence between two primary index tumors.
The survival curves of patients with second esophageal
cancer versus other non-esophageal second cancers were
calculated by the Kaplan-Meier method and the differ-
ences between these two groups were presented by hazard
ratio using the Cox proportional hazards model. All statis-
tical tests were two-sided and P < 0.05 was considered sta-
tistically significant.
Results
Patient characteristics
Of the total 33,787 cases (30,176 males and 3,611
females) with oral and pharyngeal carcinoma diagnosed
as the first malignancy and complete data available for
analysis, which included oral cavity (26,166 cases),
oropharynx (3,403 cases) and hypopharynx (4,218
cases), 2,379 cases (7.04%) developed at least one second
primary malignancy and 200 cases (0.59%) developed a
second primary esophageal cancer during 116,912 per-
son-years of follow-up. The characteristics of the patient
population are listed in Table 1. Within this cohort, the
average follow-up time was 3.46 years, including 21,704
cases (64%) followed up for at least one year, 4,666 cases
(14%) for 5-10 years and 3,144 cases (9%) for >10 years.
The mean age at diagnosis of first malignancy was 53.63
(age range 20 to 98) years for the three cancers. For those
diagnosed with second primary esophageal cancer, the
mean diagnosis age was 56.70 (age range 36 to 83) years
with an average interval of 2.52 years (time interval range
0.09 to 12.65) between the diagnosis of the two primary
cancers.
Table 1: Characteristics of population-based cohort of 33,787 patients diagnosed the first primary cancer as oral and pharyngeal 
(including oral cavity, oropharyngeal, or hypopharyngeal) carcinoma, 1979-2003.
Oral cavity Oropharynx Hypopharynx
ICD 140, 141, 143, 144, 145 146, 149 148
No. with first primary cancer All 26,166 3,403 4,218
M 23,320 2,788 4,068
F 2,846 615 150
No. who developed a second primary cancer (%)* All 1,800 (6.88) 232 (6.82) 347 (8.23)
M 1,654 (7.09) 197 (7.07) 335(8.24)
F 146 (5.13) 35 (5.69) 12 (8.00)
No. who developed the second esophageal cancer (%)* All 99 (0.38) 30 (0.88) 71 (1.68)
M 99 (0.42) 29 (1.04) 69 (1.70)
F 0 (0) 1 (0.16) 2 (1.33)
Average (± sd) age at diagnosis of first cancer (yrs) 52.70 ± 12.54 54.75 ± 13.17 58.48 ± 11.75
Average (± sd) age at diagnosis of a second cancer (yrs) 56.70 ± 11.87 57.70 ± 12.11 60.12 ± 11.38
Average (± sd) age at diagnosis of the second esophageal cancer (yrs.) 57.59 ± 10.46 51.77 ± 10.52 57.55 ± 10.15
Average (± sd) interval between the first primary and second cancers (yrs.) 3.25 ± 3.51 2. 64 ± 3.47 2.47 ± 3.32
Average (± sd) interval between the first primary and the second esophageal 
cancer (yrs.)
3.10 ± 2.64 1.24 ± 1.16 2.23 ± 2.76
Average follow-up (yrs) 3.60 ± 4.15 3.39 ± 4.32 2.65 ± 3.80
*percentage out of number with first primary cancer.
sd = standard deviation; yrs = years.BMC Cancer 2009, 9:373 http://www.biomedcentral.com/1471-2407/9/373
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Risk of second cancer at digestive tracts stratified by the 
site of primary oral and pharyngeal carcinoma
Second cancer risk in the digestive tract including esopha-
gus, stomach, colon, and rectum, was analyzed in patients
with primary oral and pharyngeal carcinoma. Standard-
ized incidence ratios (SIRs) and corresponding 95% con-
fidence intervals (CIs) were calculated by the anatomic
site of origin of the primary cancer (Table 2). Among these
four digestive tract organs, the esophagus was the only site
of second cancer with excess risk in patients with oral and
pharyngeal carcinoma. Interestingly, the risk was
increased as the primary index tumor was located in prox-
imity to the esophagus, in a descending sequence of
hypopharynx (SIR = 22.76, 95% CI 17.77-28.70) >
oropharynx (SIR = 14.29, 95% CI 9.64-20.39) > oral cav-
ity (SIR = 5.57, 95% CI 4.53-6.78). The risks of second
colon and rectum cancer were similar to the general pop-
ulation, whereas second stomach cancer was decreased in
oral cavity cancer patients (SIR = 0.58, 95% CI 0.39-0.84),
suggesting that it occurred less frequently than expected.
Risk of second esophageal cancer stratified by follow-up 
interval after oral and pharyngeal carcinoma
To explore the latency of development of the second
esophageal cancer, the standardized incidence ratio esti-
mates were stratified by interval since the first diagnosis of
oral and pharyngeal cancers (Table 3). The entire follow-
up period was categorized into 3 intervals: 1 year, 1-5
years and >5 years. The risk of developing a second
esophageal cancer peaked during the first-year of follow
up, with the descending sequence of hypopharynx (SIR =
81.13, 95% CI 59.57-110.88) > oropharynx (SIR = 75.00,
95% CI 47.12-116.41) > oral cavity (SIR = 18.18, 95% CI
12.62-25.47), and decreased with follow-up time but
remained elevated for 5 years after diagnosis of the first
primary cancer.
Age trend of second esophageal cancer
To study the trend of the second esophageal cancer with
age at initial diagnosis of the oral and pharyngeal carci-
noma, we stratified their standardized incidence ratios
(SIRs) according to three age groups (<50, 50-60 and >60)
(Table 4). The occurrence of second esophageal cancer
exhibited a strong trend with the onset age of oral and
pharyngeal carcinoma. The risk was much higher in
younger patients, particularly those diagnosed before 50
years of age, the SIR was drastically high, in a descending
order of hypopharynx (SIR = 71.53, 95% CI 43.67-
110.48) > oropharynx (SIR = 46.49, 95% CI 25.40-78.01)
Table 2: Risk for esophagus (ICD-9: 150), stomach (ICD-9: 151), colon (ICD-9:153) and rectum (ICD-9: 154) as the second primary 
cancer site among 33,787 oral/pharyngeal cancer (ICD-9: 140-149, except 142 and 147) patients.
First primary 
cancer site 
(ICD-9)
Esophagus Stomach Colon Rectum
Sex OPY O E SIR
(95% CI)
OE S I R
(95% CI)
OE S I R
(95% CI)
OE S I R
(95% CI)
Oral cavity
(140-1, 143-5)
All 90644 99 17.73 5.57
(4.53-6.78)
28 48.02 0.58
(0.39-0.84)
39 41.63 0.93
(0.66-1.28)
35 36.15 0.97
(0.67-1.34)
M 77527 99 17.25 5.74
(4.66-6.99)
28 42.82 0.65
(0.43-0.95)
31 34.68 0.89
(0.61-1.27)
29 30.90 0.94
(0.63-1.35)
F 13117 0 0.48 0
(NA)
05 . 2 0 0
(NA)
8 6.95 1.15
(0.50-2.27)
6 5.25 1.14
(0.42-2.49)
Oropharynx
(146,149)
All 11303 30 2.11 14.29
(9.64-20.39)
2 6.51 0.31
(0.03-1.11)
05 . 6 3 0
(NA)
3 4.77 0.63
(0.13-1.83)
M8 4 7 42 92 . 0 1 14.43
(9.66-20.72)
05 . 4 8 0
(NA)
04 . 2 5 0
(NA)
3 3.73 0.80
(0.16-2.35)
F 2829 1 0.09 11.11
(0.15-61.82)
2 1.03 1.94
(0.22-7.01)
01 . 3 8 0
(NA)
01 . 0 4 0
(NA)
Hypopharynx
(148)
All 11212 71 3.12 22.76
(17.77-28.70)
6 9.40 0.64
(0.23-1.39)
7 7.18 0.97
(0.39-2.01)
8 6.18 1.29
(0.56-2.55)
M 10721 69 3.09 22.33
(17.37-28.26)
6 9.17 0.65
(0.24-1.42)
6 6.87 0.87
(0.32-1.90)
8 5.95 1.34
(0.58-2.65)
F 491 2 0.02 100
(11.23-361.05)
00 . 2 3 0
(NA)
1 0.30 3.33
(0.04-18.55)
00 . 2 3 0
(NA)
Bold indicates statistical significance.
OPY = observed person years; SIR = standardized incidence ratio; O = observed numbers of second primary cancers; E = expected numbers of 
second primary cancers; CI = confidence interval; NA = not assessable.BMC Cancer 2009, 9:373 http://www.biomedcentral.com/1471-2407/9/373
Page 5 of 11
(page number not for citation purposes)
> oral cavity (SIR = 11.01, 95% CI 7.83-15.05). For those
aged >50, their SIRs also remained significantly high.
Risk of second esophageal cancer stratified by calendar 
year at diagnosis of oral and pharyngeal carcinoma
SIRs stratified for calendar year at diagnosis of the first pri-
mary cancer of the oral cavity, oropharynx and hypophar-
ynx were calculated for second primary esophageal cancer
across the diagnostic periods 1979-1993 and 1994-2003
(Table 5). The SIR demonstrated a trend of increasing
excess risk of second esophageal cancer in oropharyngeal
carcinoma after 1994 but remained relatively stable in
oral cavity and hypopharyngeal carcinomas.
Cumulative incidence rates of all second cancers versus the 
second esophageal cancer
The estimated overall risk of developing all types of sec-
ond cancers after primary oral and pharyngeal carcinoma
in the survivors' cohort was calculated with death treated
as a competing risk (Figure 1A), while the estimated over-
all risk of developing a second esophageal cancer after pri-
mary oral and pharyngeal carcinoma in the survivors'
Table 3: Risk for second esophageal cancer by follow-up interval after the diagnosis of oral/pharyngeal cancer.
First primary cancer site (ICD-9) Follow-up time (yrs) OPY O E SIR
(O/E)
95% CI
Oral cavity
(140-1,143-145)
1 10352 34 1.87 18.18 (12.62-25.47)
1-5 25205 45 4.91 9.16 (6.69-12.27)
> 5 55087 20 10.96 1.82 (1.11--2.82)
Oropharynx
(146, 149)
1 1449 21 0.28 75.00 (47.12-116.41)
1-5 2862 9 0.53 17.31 (7.83-32.56)
> 5 6992 0 1.30 0 (NA)
Hypopharynx
(148)
1 2119 43 0.53 81.13 (59.57-110.88)
1-5 3005 20 0.77 25.97 (15.76-39.87)
> 5 6088 8 1.82 4.40 (1.89 -- 8.66)
Bold indicates statistical significance.
OPY = observed person years; SIR = standardized incidence ratio; O = observed numbers of second esophageal cancer; E = expected numbers of 
second esophageal cancer; CI = confidence interval;
NA = not assessable; yrs = years.
Table 4: Risk for second esophageal cancer by age at initial onset among 33,782 patients with oral/pharyngeal cancer.
First primary cancer site (ICD-9) Age
(yrs)
OPY O E SIR
(O/E)
95% CI
Oral cavity
(140-1, 143-145)
50 39031 39 3.54 11.01 (7.83-15.05)
50-60 24591 30 5.65 5.31 (3.58-7.58)
> 60 27022 30 8.54 3.51 (2.37-5.02)
Oropharynx
(146, 149)
50 4333 14 0.30 46.49 (25.40-78.01)
50-60 2869 11 0.62 17.73 (8.84-31.73)
> 60 4101 5 1.18 4.22 (1.36-9.85)
Hypopharynx
(148)
50 2479 20 0.28 71.53 (43.67-110.48)
50-60 3300 26 0.83 31.22 (20.39-45.75)
> 60 5433 25 2.01 12.47 (8.07-18.41)
Bold indicates statistical significance.
OPY = observed person years; SIR = standardized incidence ratio; O = observed numbers of second esophageal cancer; E = expected numbers of 
second esophageal cancer; CI = confidence interval; yrs = years.BMC Cancer 2009, 9:373 http://www.biomedcentral.com/1471-2407/9/373
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cohort was calculated with death and non-esophageal
cancers treated as competing risks (Figure 1B).
The overall cumulative risks of all second cancers at 5, 10,
15 years after the first primary cancer diagnosis were esti-
mated to be 6.13%, 9.02%, and 10.36%, respectively, for
oral cavity cancer; 6.48%, 7.87%, and 8.66%, respectively,
for oropharyngeal cancer; and 7.57%, 9.07%, and 9.94%,
respectively, for hypopharyngeal cancer. There was no risk
plateau and the cumulative incidences over time did not
differ each other among oral cavity, oropharynx and
hypopharynx (all P- values > 0.05), indicating that they
were at equivalent risk for developing second cancers
without specified.
When the second cancer was restricted to esophageal can-
cer, the overall cumulative risks at 5, 10, 15 years after pri-
mary cancer were estimated to be 0.34%, 0.55%, and
0.55%, respectively, for oral cavity cancer; 0.98%, 0.98%,
and 0.98%, respectively, for oropharyngeal cancer; and
1.57%, 1.90%, and 2.02%, respectively, for hypopharyn-
geal cancer. The risk plateau was seen in all the cumulative
incidence curves. The cumulative incidence curves for
developing a second esophageal cancer were statistically
different when compared each other (all P-values < 0.01),
in a sequence of hypopharynx > oropharynx > oral cavity.
The trend in Figure 1B was in consistent with the results
observed in Table 2 and Table 3.
Overall survival of the oral and pharyngeal carcinoma 
patients
The overall 5-year survival rate for all oral and pharyngeal
carcinoma patients in our cohort was 50.2 ± 0.002% with
a median survival of 3.93 ± 0.08 years. For stratification by
tumor site, the 5-year survival rate was 50%, 41%, and
28% for oral cavity, oropharynx, and hypopharynx, with
the median survival time of 5.11, 2.66 and 1.46 years,
respectively (Figure 2). The survivals were significantly
different each other (all P-values < 0.001), in which
hypopharyngeal cancer was associated with the worst sur-
vival, followed by oropharyngeal cancer, when compared
to oral cavity cancer.
Survival time after second esophageal cancer versus non-
esophagus second cancers
The survival time after diagnosis of the second esophageal
cancer as compared to other non-esophagus second can-
cers was calculated by the Kaplan-Meier method. The
results suggest that irrespective of primary site, second
esophageal cancer had a shorter survival than other non-
esophagus second cancers (Hazard ratio, HR= 2.081, P-
value < 0.001) (Figure 3A). For specific primary tumor
site, the median survival after developing a second
esophageal cancer was 0.73 ± 0.06, 0.60 ± 0.09, and 0.81
± 0.09 years for oral cavity, oropharynx, and hypophar-
ynx, respectively, whereas the median survivals after
developing other non-esophagus second cancers were
1.85 ± 0.10, 1.63 ± 0.20, and 1.60 ± 0.24 years for oral cav-
ity, oropharynx, and hypopharynx, respectively. The
results revealed that second esophageal cancer had a
shorter survival than other non-esophageal second can-
cers (HR = 2.01, 3.80, 1.58 for oral cavity, oropharynx and
hypopharynx, respectively, all P-values  0.002) (Figure
3B).
Discussion
Second primary malignancies, especially esophageal can-
cer, are known to be one of the major causes of treatment
failure in patients with oral and pharyngeal carcinoma,
particularly those with early stage. An early diagnosis of
asymptomatic esophageal cancer can prolong survival
and enables treatment by endoscopic mucosal resection
[25]. However, in our study, the incidence of developing
a second primary esophageal cancer was only 0.59%.
Table 5: Risk for second esophageal cancer by calendar period at diagnosis of oral/pharyngeal cancer.
First primary cancer site (ICD-9) Calendar year OPY O E SIR
(O/E)
(95% CI)
Oral cavity
(140-1, 143-145)
1979-1993 20031 27 8.94 8.94 (5.89-13.01)
1994-2003 70613 72 4.89 4.89 (3.83-6.16)
Oropharynx
(146, 149)
1979-1993 2930 2 4.55 4.55 (0.51-16.41)
1994-2003 8373 28 16.87 16.87 (11.21-24.38)
Hypopharynx
(148)
1979-1993 3052 18 25.35 25.35 (15.02-40.07)
1994-2003 8160 53 21.99 21.99 (16.47-28.77)
Bold indicates statistical significance.
OPY = observed person years; SIR = standardized incidence ratio; O = observed numbers of second esophageal cancer; E = expected numbers of 
second esophageal cancer; CI = confidence interval.BMC Cancer 2009, 9:373 http://www.biomedcentral.com/1471-2407/9/373
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Cumulative incidence rates of (A) all the second cancers, and (B) second primary esophageal cancer for a total of 33,787  patients with primary oral/pharyngeal carcinoma Figure 1
Cumulative incidence rates of (A) all the second cancers, and (B) second primary esophageal cancer for a total 
of 33,787 patients with primary oral/pharyngeal carcinoma.BMC Cancer 2009, 9:373 http://www.biomedcentral.com/1471-2407/9/373
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Because of the relatively small proportion, routine panen-
doscopy as the initial evaluation and follow-up examina-
tion for every oral and pharyngeal carcinoma patient has
remained controversial in Taiwan. For cost-effectiveness,
it would be more logical to identify patients at the highest
risk and tailor the application of intensive follow-up
screening to the estimated risk in each individual case. We
found the incidence and risk of developing a second pri-
mary esophageal cancer differed according to the site of
the primary index tumor, most frequently seen in
hypopharyngeal cancer (71/4,218= 1.68%, SIR= 22.76,
95% CI 17.77-28.70), followed by oropharyngeal cancer
(30/3,403= 0.88%, SIR= 14.29, 95% CI 9.64-20.39) and
the least in the oral cavity cancer (99/26,166= 0.38%,
SIR= 5.57, 95% CI 4.53-6.78). The longer the patients sur-
vive the first cancer, the greater their risk of developing a
second primary. Comparing to oropharyngeal cancer and
oral cavity cancer with 41% and 50% five-year survival
rate respectively, hypopharyngeal cancer has a relatively
low five-year survival of only 28% and thus less opportu-
nity to develop a second primary cancer. However, it was
noted that hypopharyngeal cancer had the highest risk of
developing a second esophageal cancer.
In this analysis, the risk was extraordinary high for
patients with initial cancer onset at age 50 and those
with follow-up interval  1 year. A multicentric study pub-
lished by Chuang et al [14] also showed the similar find-
ings. These patients may justify more close surveillance
and periodic panendoscopies. The increased risk for
young patients could be explained by a possible inherited
genetic susceptibility to cancer in addition to environ-
mental risk factors. There is evidence that genetically pre-
disposed individuals tend to develop a second primary
malignancy following head and neck cancer [26]. How-
ever, there are still some limitations in this study. We
could not exclude the possibility that the observed excess
risk in the first year of follow-up might be due to more fre-
quent examinations (surveillance bias), or a misclassifica-
tion of the local spread out of the primary tumor to
esophagus as a second primary.
The etiologic factors for developing a subsequent esopha-
geal cancer in oral and pharyngeal carcinoma patients
remain to be defined. Alcohol consumption and cigarette
smoking are major risk factors in oral and pharyngeal car-
cinoma as well as esophageal cancer [26,27]. In Taiwan,
betel quid chewing is also associated with higher risk of
oral cavity and esophageal cancer [28], and an interaction
between cigarette, alcohol and betel quid use on esopha-
geal cancer risk has been reported [29].
Field cancerization [30] can explain in part the develop-
ment of multiple tumors by shared common risk factors,
Kaplan-Meier survival curves of all the patients stratified by index tumor site in the oral cavity (26,166 cases), oropharynx  (3,403 cases) and hypopharynx (4,218 cases) Figure 2
Kaplan-Meier survival curves of all the patients stratified by index tumor site in the oral cavity (26,166 cases), 
oropharynx (3,403 cases) and hypopharynx (4,218 cases).BMC Cancer 2009, 9:373 http://www.biomedcentral.com/1471-2407/9/373
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The survival curves of second esophageal cancer versus non-esophageal second cancers for (A) all the patients with oral/pha- ryngeal carcinoma; and (B) patients stratified by index tumor site Figure 3
The survival curves of second esophageal cancer versus non-esophageal second cancers for (A) all the patients 
with oral/pharyngeal carcinoma; and (B) patients stratified by index tumor site.BMC Cancer 2009, 9:373 http://www.biomedcentral.com/1471-2407/9/373
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where the carcinogenic effects of alcohol, tobacco and
betel nut may simultaneously act on the entire mucosa of
mouth, pharynx and aerodigestive tract to trigger the
development of multiple cancers that are independent of
each other. As to other agent, the association of human
papilloma virus (HPV) with oropharyngeal cancer (45%),
particularly Waldeyer's tonsillar ring (60%), has been
reported [31], yet its etiologic role in the development of
esophageal cancer is not conclusive, particularly in differ-
ent geographic areas [32,33]. Interestingly, studies from
China [34,35] have reported relatively high percentages of
HPV-positive esophageal cancer cases when compared to
reports from Western countries. In contrast, HPV was not
found to be associated with esophageal cancer in Taiwan
[36] and Korea [37]. In addition to environmental factors
such as tobacco, alcohol, betel and HPV, there was an age
trend for esophageal cancer as a second primary, with SIR
higher in younger onset patients than older onset
patients, suggesting that genetic predisposition may play
a role.
Regardless of primary site, the median survival after devel-
oping a second esophageal cancer did not exceed one year.
Furthermore, among those with a second cancer, those
with an esophageal cancer had a risk of death over 2-fold
compared to those with a non-esophageal second cancer.
The dismal prognosis related to a second esophageal can-
cer may be attributable to late diagnosis and in some
patients, the inability to receive aggressive therapy
because of therapy for the first malignancy. The reduction
of risk for gastric cancer in the oral cavity cancer patients
is an unanswered question arising from our study. In a
single-institute study with 1,138 cases of malignancies of
the head and neck in Japan [38], the risk of second gastric
cancer was even higher than that of second esophageal
cancer. This is in contrast to our findings that no excess
risk was observed with non-esophageal cancers (i.e. stom-
ach, colon and rectum). The discrepancy was intriguing
and could be due to selection bias in a single hospital or
geographic variations. Further studies are needed to eluci-
date their associations.
Conclusion
The results of our study observed strong associations of
first primary oral and pharyngeal carcinoma with second
primary esophageal cancer, which had a great impact on
survival. This study represents the first population-based
study in Asia attempting to stratify the patients of oral and
pharyngeal carcinoma by their risk of developing a second
esophageal cancer. Such knowledge will aid in the appro-
priate selection of high-risk patients for a follow-up sur-
veillance program, and can be very useful for some
countries of Asia and the South Pacific where the inci-
dence rates of oral and pharyngeal carcinoma are high,
but implementation of such program is not easy due to
limited resources.
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